Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atara Biotherapeutics ( (ATRA) ) has provided an update.
On February 20, 2026, Atara Biotherapeutics amended its existing Purchase and Sale Agreement with a fund managed by HealthCare Royalty, pushing back a one-time $9.0 million milestone payment tied to its Pierre Fabre commercialization deal from June 30, 2026 to January 1, 2028. The revised timing eases near-term cash obligations as Atara and its partner work through U.S. regulatory issues for tabelecleucel while continuing to serve patients in Europe.
In exchange for the extension, Atara issued HCRx a warrant to purchase up to 400,000 shares of its common stock at a nominal exercise price of $0.0001 per share, exercisable immediately with no expiration but subject to a 4.99% beneficial ownership cap and cashless exercise provisions. The warrant, issued under a private placement exemption, underscores HCRx’s ongoing support and gives the royalty fund equity-linked upside as Atara pursues a potential U.S. approval path for tabelecleucel and seeks to strengthen its financial flexibility.
The most recent analyst rating on (ATRA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
The score is primarily held down by weak financial performance (negative equity and ongoing cash burn) and very bearish technicals (price far below key moving averages with negative MACD). A highly negative corporate event (FDA CRL for EBVALLO) further increases risk, while the low P/E provides only partial support given the underlying uncertainty.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc. is a Southern California-based biotechnology company focused on developing off-the-shelf, allogeneic T-cell immunotherapies for difficult-to-treat cancers and autoimmune conditions. Leveraging a novel Epstein-Barr virus (EBV) T-cell platform that does not require T-cell receptor or HLA gene editing, Atara has built a portfolio of investigational therapies targeting EBV-driven diseases and is the first company to receive regulatory approval for an allogeneic T-cell immunotherapy.
The company’s lead programs include tabelecleucel (tab-cel), aimed at treating relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD), an ultra-rare and aggressive lymphoma. Atara partners with Pierre Fabre Medicament on commercialization efforts and positions itself in the cell therapy market as a pioneer in rapidly deliverable, inventory-based cell therapies for patients with significant unmet medical needs.
Average Trading Volume: 296,337
Technical Sentiment Signal: Strong Sell
Current Market Cap: $31.94M
See more data about ATRA stock on TipRanks’ Stock Analysis page.